TBL1XR1
Basic information
Region (hg38): 3:177019340-177228000
Links
Phenotypes
GenCC
Source:
- Pierpont syndrome (Definitive), mode of inheritance: AD
- intellectual disability, autosomal dominant 41 (Moderate), mode of inheritance: AD
- Pierpont syndrome (Moderate), mode of inheritance: AD
- Pierpont syndrome (Strong), mode of inheritance: AD
- intellectual disability, autosomal dominant 41 (Strong), mode of inheritance: AD
- complex neurodevelopmental disorder (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Intellectual developmental disorder, autosomal dominant 41; Pierpont syndrome | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic | 9450851; 16007632; 22495309; 23160955; 24891185; 25102098; 26769062 |
ClinVar
This is a list of variants' phenotypes submitted to
- Pierpont syndrome (11 variants)
- not provided (11 variants)
- Intellectual disability, autosomal dominant 41 (2 variants)
- Malignant lymphoma, large B-cell, diffuse (1 variants)
- TBL1XR1-related disorder (1 variants)
- Intellectual disability, autosomal dominant 41;Pierpont syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TBL1XR1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 106 | 109 | ||||
missense | 11 | 35 | 143 | 190 | ||
nonsense | 4 | |||||
start loss | 0 | |||||
frameshift | 13 | |||||
inframe indel | 11 | 15 | ||||
splice donor/acceptor (+/-2bp) | 8 | |||||
splice region | 1 | 16 | 27 | 4 | 48 | |
non coding | 79 | 33 | 115 | |||
Total | 23 | 51 | 160 | 186 | 34 |
Variants in TBL1XR1
This is a list of pathogenic ClinVar variants found in the TBL1XR1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-177025496-C-G | Uncertain significance (Dec 01, 2021) | |||
3-177025498-C-T | Pierpont syndrome • Inborn genetic diseases | Likely benign (Oct 16, 2023) | ||
3-177025501-T-C | Pierpont syndrome | Likely benign (Jan 29, 2024) | ||
3-177025504-C-G | Pierpont syndrome | Likely benign (Sep 16, 2021) | ||
3-177025505-C-T | Uncertain significance (Aug 25, 2022) | |||
3-177025506-G-A | Pierpont syndrome | Uncertain significance (Nov 02, 2022) | ||
3-177025511-T-A | Uncertain significance (Apr 16, 2023) | |||
3-177025516-T-A | Pierpont syndrome | Likely benign (Aug 10, 2023) | ||
3-177025516-T-G | Inborn genetic diseases • Pierpont syndrome | Likely benign (Dec 18, 2023) | ||
3-177025520-C-T | Pierpont syndrome | Uncertain significance (Jan 13, 2021) | ||
3-177025541-T-C | Pierpont syndrome | Likely benign (Oct 17, 2023) | ||
3-177025541-TAATC-T | Pierpont syndrome | Benign (Oct 03, 2023) | ||
3-177026243-GA-G | Benign (Aug 10, 2019) | |||
3-177026353-A-G | Pierpont syndrome | Likely benign (Nov 27, 2023) | ||
3-177026355-A-T | Pierpont syndrome | Likely benign (Dec 09, 2022) | ||
3-177026360-TTACTA-T | Pierpont syndrome | Likely benign (Dec 16, 2023) | ||
3-177026370-T-C | Pierpont syndrome | Uncertain significance (Nov 04, 2022) | ||
3-177026373-T-G | Pierpont syndrome | Uncertain significance (Aug 14, 2023) | ||
3-177026379-A-G | Pierpont syndrome | Likely benign (Jul 24, 2022) | ||
3-177026385-T-C | Pierpont syndrome | Likely benign (Jul 14, 2023) | ||
3-177026395-C-T | Intellectual disability | Likely pathogenic (Sep 10, 2020) | ||
3-177026399-C-T | Uncertain significance (Feb 19, 2017) | |||
3-177026403-G-A | Pierpont syndrome | Likely benign (Aug 02, 2023) | ||
3-177026405-C-T | Intellectual disability, autosomal dominant 41 • TBL1XR1-related disorder | Uncertain significance (Feb 01, 2022) | ||
3-177026410-G-A | Uncertain significance (Oct 01, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TBL1XR1 | protein_coding | protein_coding | ENST00000430069 | 14 | 178119 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 0.0000491 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.20 | 69 | 260 | 0.266 | 0.0000120 | 3404 |
Missense in Polyphen | 5 | 74.44 | 0.067168 | 1045 | ||
Synonymous | -0.375 | 94 | 89.5 | 1.05 | 0.00000443 | 942 |
Loss of Function | 4.91 | 0 | 28.1 | 0.00 | 0.00000144 | 335 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units. Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of the N-Cor corepressor complex that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of N-Cor complex, thereby allowing cofactor exchange, and transcription activation. {ECO:0000269|PubMed:14980219}.;
- Disease
- DISEASE: Pierpont syndrome (PRPTS) [MIM:602342]: An autosomal dominant syndrome characterized by multiple congenital anomalies, global developmental delay, learning disability, palmar and plantar fat pads, and distinctive facial characteristics, especially when smiling. {ECO:0000269|PubMed:26769062}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mental retardation, autosomal dominant 41 (MRD41) [MIM:616944]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD41 patients manifest delayed psychomotor development, variable severity of intellectual disability, and delayed language. Non-specific dysmorphic features and autistic behavior is observed in some patients. {ECO:0000269|PubMed:22495309, ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:25102098, ECO:0000269|PubMed:27133561}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Wnt signaling pathway - Homo sapiens (human);Disease;Signal Transduction;Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha);Metabolism of lipids;HDACs deacetylate histones;Chromatin modifying enzymes;Metabolism;Signaling by NOTCH1;Signaling by NOTCH;Chromatin organization;Constitutive Signaling by NOTCH1 PEST Domain Mutants;Signaling by NOTCH1 PEST Domain Mutants in Cancer;Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants;Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer;Signaling by NOTCH1 in Cancer;Regulation of nuclear beta catenin signaling and target gene transcription;Diseases of signal transduction;NOTCH1 Intracellular Domain Regulates Transcription
(Consensus)
Recessive Scores
- pRec
- 0.254
Intolerance Scores
- loftool
- rvis_EVS
- -0.16
- rvis_percentile_EVS
- 41.25
Haploinsufficiency Scores
- pHI
- 0.930
- hipred
- Y
- hipred_score
- 0.783
- ghis
- 0.686
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.937
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tbl1xr1
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); liver/biliary system phenotype;
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;blastocyst hatching;response to dietary excess;regulation of transcription by RNA polymerase II;lipid catabolic process;histone deacetylation;regulation of lipid metabolic process;multicellular organism growth;proteasome-mediated ubiquitin-dependent protein catabolic process;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;white fat cell differentiation;fat pad development;regulation of triglyceride metabolic process;positive regulation of canonical Wnt signaling pathway
- Cellular component
- histone deacetylase complex;nucleus;nucleoplasm;transcriptional repressor complex;mitotic spindle
- Molecular function
- transcription corepressor activity;protein binding;beta-catenin binding;histone binding;transcription regulatory region DNA binding;protein N-terminus binding